[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tscan Therapeutics Inc (TCRX)

Tscan Therapeutics Inc (TCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 71,697
  • Shares Outstanding, K 56,902
  • Annual Sales, $ 10,330 K
  • Annual Income, $ -129,770 K
  • EBIT $ -136 M
  • EBITDA $ -133 M
  • 60-Month Beta 1.06
  • Price/Sales 6.67
  • Price/Cash Flow N/A
  • Price/Book 0.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.28
  • Number of Estimates 4
  • High Estimate $-0.20
  • Low Estimate $-0.48
  • Prior Year $-0.28
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9994 +26.08%
on 04/13/26
1.4700 -14.29%
on 04/20/26
+0.2000 (+18.87%)
since 04/08/26
3-Month
0.9061 +39.06%
on 02/12/26
1.4700 -14.29%
on 04/20/26
+0.2300 (+22.33%)
since 02/06/26
52-Week
0.8824 +42.79%
on 12/19/25
2.5700 -50.97%
on 10/16/25
-0.1200 (-8.70%)
since 05/08/25

Most Recent Stories

More News
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Early data on patients treated in Cohort C of the ALLOHAâ„¢ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 â„¢ ) planned for the second...

TCRX : 1.2600 (+4.13%)
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.2600 (+4.13%)
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.2600 (+4.13%)
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Presented positive updated data from the ALLOHA â„¢ Phase 1 heme trial at 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort...

TCRX : 1.2600 (+4.13%)
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHAâ„¢ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03...

TCRX : 1.2600 (+4.13%)
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.2600 (+4.13%)
TScan Therapeutics Announces Positive Updated Data from the ALLOHAâ„¢ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up...

TCRX : 1.2600 (+4.13%)
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHAâ„¢ Phase 1 Trial and Future Market Opportunities

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.2600 (+4.13%)
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA â„¢ Phase 1 heme trial to be presented at the 67 th American Society...

TCRX : 1.2600 (+4.13%)
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.2600 (+4.13%)

Business Summary

TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 1.4333
2nd Resistance Point 1.3867
1st Resistance Point 1.3233
Last Price 1.2600
1st Support Level 1.2133
2nd Support Level 1.1667
3rd Support Level 1.1033

See More

52-Week High 2.5700
Fibonacci 61.8% 1.9253
Fibonacci 50% 1.7262
Fibonacci 38.2% 1.5271
Last Price 1.2600
52-Week Low 0.8824

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.